View all companies
Recommendation
Start reading our world-class research today.
Already have an account?
Log in
2 articles for iX Biopharma Ltd
iX Biopharma: Multiple share price catalysts
Outlicensing of Wafermine for Phase 3 trials is a major share price catalyst for the company to enter the estimated US$19bn global opioid industry. Operating expenses are assumed largely stable. The next phase is to license the drug for Phase 3 trial...
Paul Chew @ PhillipCapital 20 October 2021
iX Biopharma: Initiation – Potency for the long haul
iX Biopharma is a pharmaceutical company with a full suite of operations from the development to commercialisation of specialty pharmaceutical and nutraceutical drugs through its patented sublingual drug delivery system, WaferiX. Since its listing on...
Tay Wee Kuang @ PhillipCapital 12 November 2020
Details
Singapore
Asia
Capital Goods
About
iX Biopharma Ltd is a specialty pharmaceutical company. The Company works primarily on drug delivery and formulation required to reduce the loss of drugs due to hepatic and gastrointestinal metabolism.
